GO
Loading...

Enter multiple symbols separated by commas

Novartis AG

More

  • NEW YORK, June 30- The United States says Novartis AG should pay as much as $3.35 billion in damages and civil fines because the Swiss drugmaker used kickbacks to boost sales of two drugs covered by Medicare and Medicaid. In papers filed Monday night in Manhattan federal court, the government said it deserves that sum under the federal False Claims Act over...

  • BASEL, Switzerland, June 30- Novartis plans to test a novel pricing model with some customers when it launches its keenly awaited new heart failure drug Entresto, the Swiss company's head of pharmaceuticals said on Tuesday. How the product should be priced, however, is a dilemma for Novartis, since the company wants to reach as many patients as possible and it knows...

  • BASEL, Switzerland, June 29- Drugmakers said on Monday they would continue to ship medicines to Greece in coming weeks, despite mounting unpaid bills, but warned supplies could be in jeopardy if Europe did not take emergency action. A copy of the letter to EU Health Commissioner Vytenis Andriukaitis from Richard Bergstrom, director general of the European...

  • Switzerland's Novartis buys US biotech firm Spinifex Monday, 29 Jun 2015 | 4:03 AM ET

    BERLIN— Swiss drug manufacturer Novartis says it is buying Spinifex Pharmaceuticals, a U.S.-based biotechnology company that specializes in developing treatments for chronic pain. Novartis didn't disclose financial details Monday of the agreement to buy privately held Spinifex, which has its headquarters in Stamford, Connecticut, and an office in...

  • BASEL, Switzerland, June 29- Swiss drugmaker Novartis AG boosted its presence in pain management on Monday by agreeing to buy U.S.-Australian biotech firm Spinifex Pharmaceuticals, the companies said in separate statements on Monday. Spinifex said Novartis was paying $200 million upfront and Spinifex shareholders could get further payments based on...

  • Philip Morris International Inc has hired more than 400 scientists and technical staff at its research facility in Neuchatel, Switzerland, including toxicologists, chemists, biologists, biostatisticians and regulatory affairs experts. Altria Group Inc, makers of Marlboro, has recruited dozens of scientific and healthcare experts, as have independent...

  • LONDON, June 22- GlaxoSmithKline has agreed to sell two meningitis vaccines to Pfizer to satisfy antitrust concerns after its recent acquisition of vaccines business of Novartis. The British drugmaker said on Monday that the total consideration for the sale of its Nimenrix and Mencevax products to Pfizer's Irish unit, including some deferred payments, was...

  • NEW YORK, June 18- A U.S. appeals court on Thursday once again invalidated a patent held by Teva Pharmaceutical Industries Ltd on its top-selling multiple sclerosis drug Copaxone, clearing the way for the launch of a cheaper, generic version. The decision, by the U.S. Court of Appeals for the Federal Circuit, the nation's top patent tribunal, was a blow to Israel's...

  • ZURICH, June 18- Novartis AG said on Thursday it expects to increase its profit margin this year as it restructures its drug portfolio and cuts costs, as well as generate cash for a higher dividend and smaller, strategic acquisitions. Novartis, the world's biggest supplier of prescription drugs by sales, is briefing investors about prospects at its research...

  • New drug compound may beat malaria with single $1 dose Wednesday, 17 Jun 2015 | 1:00 PM ET

    LONDON, June 17- Scientists have discovered a new anti-malarial compound that could treat patients with a single $1 dose, including those with strains of the mosquito-borne disease that are resistant to current drugs. In a vote of confidence for the project, German drugmaker Merck KgAA has secured the right to develop and commercialize the compound, assuming...

  • Early movers: TIF, KORS, TOL, BWS, HRL & more Wednesday, 27 May 2015 | 8:31 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Novartis digs into health tech with bet on "robotic pill" Wednesday, 27 May 2015 | 4:01 AM ET

    LONDON, May 27- Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a "robotic pill" for complex biotech drugs that would normally have to be given by injection. Rani said it would run feasibility studies over the next 18-24 months to evaluate how selected Novartis biologic medicines can be...

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.

  • Ranbaxy filed "grossly inadequate" applications seeking approval for its drugs and deceived the FDA into granting approvals and giving the company market exclusivity, the class action lawsuit asserts. The FDA has banned import of drugs from all of Ranbaxy's India- based plants under a wider scrutiny of the country's $15 billion pharmaceutical industry,...

  • Biotech investors: These are the key names to know Wednesday, 13 May 2015 | 11:53 AM ET
    Biotech

    Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.

  • Disruptor 50: No. 29 Intarcia Therapeutics Tuesday, 12 May 2015 | 7:00 AM ET
    Kurt Graves, CEO of Intarcia Therapeutics

    Investors believe Intarcia's drug-delivery system could very well upend the $55 billion worldwide market for treating Type-2 diabetes.

  • May 7- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients. The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday, however, that the injunction could take effect while Amgen's appeal is pending. The Novartis drug, Zarxio,...

  • May 7- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen Inc's blockbuster drug used to prevent infections in cancer patients. The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday, however, that the injunction could take effect while Amgen's appeal is pending. The Novartis drug, Zarxio,...

  • LONDON, May 7- GlaxoSmithKline's new chairman Philip Hampton has thrown his support behind the company's current structure and chief executive despite pressure from some shareholders for a change. Yet Hampton, also chairman of the Royal Bank of Scotland, said there is an issue about GSK's relative performance in terms of shareholder returns.